87151-63-1

Basic information

• Product Name: (+/-)-1-oxaspiro[4,5]dec-7-ene
• Synonyms: (+/-)-1-oxaspiro[4,5]dec-7-ene;1-OXA-SPIRO[4.5]DEC-7-ENE(WX685413)
• CAS NO: 87151-63-1
• Molecular Formula: C₉H₁₄O
• Molecular Weight: 138.20686
• Mol File: 87151-63-1.mol

Chemical Properties

• Appearance: /
• CAS DataBase Reference: (+/-)-1-oxaspiro[4,5]dec-7-ene(CAS DataBase Reference)
• NIST Chemistry Reference: (+/-)-1-oxaspiro[4,5]dec-7-ene(87151-63-1)
• EPA Substance Registry System: (+/-)-1-oxaspiro[4,5]dec-7-ene(87151-63-1)

Safety Data

• Hazardous Substances Data: 87151-63-1(Hazardous Substances Data)

Usage

Uses

Used in Organic Synthesis:
(+/-)-1-oxaspiro[4,5]dec-7-ene is used as a building block in the preparation of natural products and bioactive compounds. Its unique structure and reactivity make it a valuable component in the synthesis of various organic compounds.
Used in Pharmaceutical Synthesis:
(+/-)-1-oxaspiro[4,5]dec-7-ene serves as a starting material for the synthesis of pharmaceuticals. Its structural features and reactivity contribute to the development of new drugs and medicinal compounds.
Used in Agrochemical Synthesis:
(+/-)-1-oxaspiro[4,5]dec-7-ene is also utilized as a starting material for the synthesis of agrochemicals, playing a role in the development of pesticides, herbicides, and other agricultural products.
Used in Fragrance and Flavor Industry:
Due to its unique structure and aromatic properties, (+/-)-1-oxaspiro[4,5]dec-7-ene has potential applications in the fragrance and flavor industry. It can be used to create novel scents and flavors for various consumer products.

Upstream product

• 108-28-1 protoanemonin 
• 84477-25-8 1-oxaspiro<4.5>deca-3,7-dien-2-one 
• 135974-78-6 1-Oxaspiro<4.5>dec-7-en-2-one 
• 87151-66-4 3-(cyclohexa-1,4-dien-1-yl)propan-1-ol 
• 135974-94-6 1-(3-Hydroxypropyl)-3-cyclohexen-1-ol 

Downstream Products

• 5904-62-1 pyrrolidin-1-ol 

Relevant articles and documents

A practical synthesis of the kappa opioid receptor selective agonist (+)-5R,7S,8S-N-methyl-N-[7-(1-pyrrolidinyl)-1-oxospiro[4,5]dec-8-yl] benzeneacetamide (U69,593)

A novel approach to the synthesis of the kappa opioid receptor agonist U69,593 has been developed. This approach improves upon current literature methods by substituting stable and isolable cyclic sulfates for the unstable epoxides. The new approach provides access to gram quantities of the target compound and displays excellent control of the relative stereochemistry. The absolute stereochemistry as well as biological activity of the U69,593 produced by this new method was verified using X-ray crystal structure analysis and binding assays for the kappa opioid receptor. Georg Thieme Verlag Stuttgart.

General Synthesis of 1-Oxaspirodecan-2-ones and 1-Oxaspirodecanes from 5-Methylene-2(5H)-furanone

5-Methylene-2(5H)-furanone underwent Diels-Alder cycloadditions to butadiene and several acyclic and cyclic C-substituted dienes, respectively, affording bicyclic and tricyclic spiroadducts in good yields.These compounds are precursors of other unsaturated and saturated spirolactones and also spiroethers, which were obtained through simple chemical reactions, i.e., hydrogenation of C-C double bonds, reduction of the carbonyl group, and Michael addition.The synthesis of 32 spirolactones and eight spiroethers illustrates the scope and efficiency of this method.Many of these products are suitable for use as components of perfumes and aromas owing to their olfactive properties.

Analgesic 1-oxa-, aza- and thia-spirocyclic compounds

Mono-Oxa-, thiaspirocyclic-benzene-acetamide and -benzamide compounds of the formula STR1 wherein p, n, m, A, E, R, R1, R2, X, Y and Z are as defined in the specification, e.g., (±)-(5α,7α,9β)-3,4-dichloro-N-methyl-N-[7-(1-pyrrolidinyl)-1-oxaspiro[4.5]dec-8-yl]benzeneacetamide, and the pharmacologically acceptable salts thereof, are useful as analgesic compounds having low physical dependence liability, compared to morphine and methodone, and low dysphoria side effects. Some of these compounds have potent analgesic activity when administered orally, and some have low CNS sedative side effects. Pharmaceutical compositions and methods for using these compounds as analgesics are disclosed. Processes for preparing this class of compounds are also disclosed.